SwePub
Sök i LIBRIS databas

  Extended search

id:"swepub:oai:DiVA.org:oru-74426"
 

Search: id:"swepub:oai:DiVA.org:oru-74426" > Homocysteine Status...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Jernerén, FredrikUppsala universitet,Institutionen för farmaceutisk biovetenskap (author)

Homocysteine Status Modifies the Treatment Effect of Omega-3 Fatty Acids on Cognition in a Randomized Clinical Trial in Mild to Moderate Alzheimer's Disease : The OmegAD Study

  • Article/chapterEnglish2019

Publisher, publication year, extent ...

  • IOS Press,2019
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:oru-74426
  • https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-74426URI
  • https://doi.org/10.3233/JAD-181148DOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-384475URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:140849022URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Funding Agencies:Funds of CapioSwedish Alzheimer Foundation  Norwegian Research Council  Odd Fellows Swedish Society of Physicians  Lion's Sweden 
  • Background: Trials of supplementation with omega-3 fatty acids (omega 3-FAs) in patients with mild cognitive impairment or Alzheimer's disease (AD) have produced inconsistent effects on cognitive decline. There is evidence of an interaction between B vitamin status and omega 3-FAs in relation to brain atrophy and cognitive decline.Objective: We investigated whether baseline levels of plasma total homocysteine (tHcy), a marker of B vitamin status, modify the effects of omega 3-FAs supplementation on cognitive performance in moderate AD.Methods: This post hoc analysis of the OmegAD trial included 171 community-based patients with AD (MMSE >= 15): 88 patients received daily doses of 1.7 g docosahexaenoic acid and 0.6 g eicosapentaenoic acid for 6 months. Treatment outcome on cognition was analyzed according to baseline levels of tHcy using a general linear model and ANCOVA.Results: We found significant interactions between omega 3-FA supplementation and tHcy on cognition and clinical stage assessed by MMSE (p = 0.040), global CDR (p = 0.059), and CDRsob (p = 0.023), but not on ADAS-cog (p = 0.649). In patients with tHcy levels <11.7 mu mol/L, omega 3-FA supplementation improved cognitive performance as measured by MMSE (+7.1%, 95% CI: 0.59 to 13.7%, p = 0.033) and clinical status as measured by CDRsob (-22.3%, 95% CI: -5.8 to -38.7%, p = 0.009) compared with placebo.Conclusion: The effect of omega 3-FA supplementation on MMSE and CDR appears to be influenced by baseline tHcy, suggesting that adequate B vitamin status is required to obtain beneficial effects of omega 3-FA on cognition.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Cederholm, TommyKarolinska Institutet,Uppsala universitet,Geriatrik,Karolinska Univ Hosp, Theme Ageing, Stockholm, Sweden(Swepub:uu)tomce419 (author)
  • Refsum, HelgaDepartment of Nutrition, University of Oslo, Oslo, Norway; Department of Pharmacology, University of Oxford, Oxford, United Kingdom,Univ Oslo, Dept Nutr, Oslo, Norway;Univ Oxford, Dept Pharmacol, Oxford, England (author)
  • Smith, A. DavidDepartment of Pharmacology, University of Oxford, Oxford, United Kingdom,Univ Oxford, Dept Pharmacol, Oxford, England (author)
  • Turner, CherylDepartment of Pharmacology, University of Oxford, Oxford, United Kingdom,Univ Oxford, Dept Pharmacol, Oxford, England (author)
  • Palmblad, JanKarolinska Institutet (author)
  • Eriksdotter, MariaKarolinska Institutet (author)
  • Hjorth, ErikKarolinska Institutet (author)
  • Faxen-Irving, GerdKarolinska Institutet (author)
  • Wahlund, Lars-OlofKarolinska Institutet (author)
  • Schultzberg, MarianneKarolinska Institutet (author)
  • Basun, HansUppsala universitet,Geriatrik(Swepub:uu)habas169 (author)
  • Freund-Levi, Yvonne,1956-Örebro universitet,Institutionen för medicinska vetenskaper,Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Huddinge, Sweden; Center for Alzheimer Research, Division of Clinical Geriatrics, Karolinska Institutet, Huddinge, Sweden; Department of Psychiatry in Region Örebro County and School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro; Department of Old Age Psychiatry, Psychology & Neuroscience, King’s College, London, UK,Karolinska Inst, Dept Neurobiol Care Sci & Soc, Huddinge, Sweden;Karolinska Inst, Ctr Alzheimer Res, Div Clin Geriatr, Huddinge, Sweden;Orebro Univ, Dept Psychiat Reg Orebro Cty, Fac Med & Hlth, Orebro, Sweden;Orebro Univ, Sch Med Sci, Fac Med & Hlth, Orebro, Sweden;Kings Coll London, Dept Old Age Psychiat Psychol & Neurosci, London, England(Swepub:oru)yfi (author)
  • Uppsala universitetInstitutionen för farmaceutisk biovetenskap (creator_code:org_t)

Related titles

  • In:Journal of Alzheimer's Disease: IOS Press69:1, s. 189-1971387-28771875-8908

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view